Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Camptothecin
  • Immunoconjugates
  • Irinotecan
  • Triple Negative Breast Neoplasms

abstract

  • Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).

publication date

  • February 21, 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1814213

PubMed ID

  • 30786188

Additional Document Info

start page

  • 741

end page

  • 751

volume

  • 380

number

  • 8